BioSpace News Archive

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2022 financial results on Wednesday, November 9, 2022, after the close of the market.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will host a conference call on Wednesday, November 2, 2022, at 5:00pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2022.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that new data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week at The Retina Society Annual Meeting in Pasadena, California.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board.

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it will release third quarter 2022 financial results on Tuesday, November 8, 2022, after the market close.

PTC Therapeutics, Inc. announced that it has entered into a strategic financing collaboration with funds managed by Blackstone to support its mission to reach a steady-state of delivering at least one therapy every 2-3 years to continue to bring transformative medicines to patients globally.

MDxHealth SA, a commercial-stage precision diagnostics company, announced its financial results for the third quarter ended September 30, 2022.

Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 3, 2022.

Prothena Corporation plc (NASDAQ:PRTA) today announced that it will report its third quarter and first nine months of 2022 financial results on Thursday, November 3, 2022 after the close of the U.S. financial markets.

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, reported financial results for the third quarter ended September 30, 2022.